Although not approved by the Food and Drug Administration (FDA) for COVID-19, hydroxychloroquine and azithromycin have been gaining momentum as potential treatments based on results of small studies.
Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”
The FDA has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test.
Currently, there are no antivirals licensed by the FDA to treat patients with COVID-19.
The FDA has announced that it will not object to the New York State Department of Health (NYSDOH) authorizing certain laboratories in New York to start testing patients for coronavirus disease 2019 (COVID-19) once the tests have been validated.
Warning letters issued by the FDA and the Federal Trade Commission (FTC) have been sent to several companies selling fraudulent products claiming to treat or prevent coronavirus 2019 (COVID-19).
More respirators, including certain N95 masks, will be made available to healthcare personnel, according to the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).
